Trials / Completed
CompletedNCT04270669
Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration
A Nonrandomized, Open-label Study to Evaluate the Safety and Pharmacokinetics of Multiple Administration of RC28-E Injection (a Chimeric Decoy Receptor Trap Fusion Protein by Dual Blockage of VEGF and FGF-2) in Subjects With Wet Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-randomized, open-label, multicenter, 48-week study to investigate the efficacy, safety and pharmacokinetics of RC28-E injection in the treatment of patients with wet age-related macular degeneration by multiple administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | intravitreal injection of RC28-E 0.5mg | The patient received one treatment of RC28-E 0.5mg in the test group |
| BIOLOGICAL | intravitreal injection of RC28-E 1.0mg | The patient received one treatment of RC28-E 1.0mg in the test group |
| BIOLOGICAL | intravitreal injection of RC28-E2.0mg | The patient received one treatment of RC28-E 2.0mg in the test group |
Timeline
- Start date
- 2020-04-15
- Primary completion
- 2021-10-29
- Completion
- 2021-10-29
- First posted
- 2020-02-17
- Last updated
- 2022-01-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04270669. Inclusion in this directory is not an endorsement.